Q2
Sanofi sales slide on patent cliff woes
August 1, 2013Sales and Marketing Aprovel, Plavix, Q2, Sanofi
Sanofi has been hit by generic erosion for key drugs in the second quarter, but the firm is confident it …
Lipitor competition holds Pfizer back
July 31, 2013Sales and Marketing Lipitor, Pfizer, Prevnar, Q2
Pfizer’s revenues in the second quarter of 2013 fell 7% year-on-year, in part due to the loss of patent in …
Merck sees sales dip
July 31, 2013Sales and Marketing Merck, Q2, Singulair, sales
A catastrophic decline in sales of asthma medicine Singulair is among the key reasons why Merck’s pharma revenue fell 12% …
Sharp fall in sales for Bristol-Myers Squibb
July 26, 2013Sales and Marketing Avapro, BMS, Plavix, Q2
Bristol-Myers Squibb has seen a fall in sales over the past three months as it struggles with major patent losses. …
Lilly beats estimates with solid Q2 performance
July 26, 2013Sales and Marketing Q2, cymbalta, lilly, zyprexa
Lilly posted a healthy set of financials at the end of July as the company looks to keep its growth …
Strong growth for Roche in latest results
July 25, 2013Sales and Marketing Alexion, Q2, Rituxan, Roche
Roche has seen strong sales growth in the past six months as it lines up new products to replace its …
GSK sales up – impact of China allegations to follow
July 24, 2013Sales and Marketing GSK, Q2, Seretide, Seroxat, Witty, bribery, transparency
GlaxoSmithKline has reported a modest rise in sales but the fallout from China’s bribery probe dominates the firm’s release of …
Marginal sales increase for Abbott
July 18, 2013Sales and Marketing AbbVie, Abbott, Q2
Abbott’s second quarter results saw the company buffeted by currency exchange issues – primarily the yen weakening against the US …
J&J sees Q2 sales rise
July 17, 2013Sales and Marketing Elan, J&J, JJ, Q2, Synthes, sales
Johnson & Johnson saw overall sales rise 8.5% year-on-year in the second quarter of 2013, with the US healthcare group …
Shire posts strong quarter results
August 2, 2012Sales and Marketing ADHD, Adderall XR, Pfizer, Q2, Shire, results
Shire has posted a set of healthy financials for the second quarter, buoyed by its ADHD and rare drug portfolio. …
Lipitor loss continues to hit Pfizer sales
July 31, 2012Sales and Marketing Enbrel, Lipitor, Pfizer, Prevnar, Q2
Pfizer has posted a loss in revenue for the second quarter as the firm continues to feel the impact of …
Bayer raises guidance after strong sales
July 31, 2012Sales and Marketing Bayer, Nexavar, Q2, Xarelto, Yasmin
The Bayer Group has raised its full-year guidance for 2012 following positive results in the second quarter. This is despite …
Merck sees growth in second quarter
July 30, 2012Sales and Marketing Cozaar, Merck, Q2, Singulair
Merck has posted a healthy sales increase for the second quarter, as its established drugs grew strongly. Sales increased 1% …
AstraZeneca sees big sales drop in Q2
July 26, 2012Sales and Marketing AstraZeneca, Brennan, Brilinta, Q2, Seroquel
AstraZeneca has today reported a large drop in revenue for the second quarter. The firm has been hit by major …
GSK falters in Q2 as austerity measures bite
July 25, 2012Sales and Marketing Benylsta, GSK, Q2, Seretide, Witty
GlaxoSmithKline posted a loss in its second quarter results, as pressure in mature markets continues to affect the firm. Pharmaceutical …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
